Objective: The study was carried out to evaluate safety and efficacy of once-a-week medication of Kasparalendronate for
inhibiting high bone turnover rate.
Material and Method: Forty-nine postmenopausal osteoporotic participants were included in the study. This investigation was carried out as an open study. The participants received the drug every week for 12 weeks. Pain, drug side effects and bone turnover markers were evaluated at the 6th week and 12th week after the first visit.
Results: None had significant complication and all could complete the trial. Thirteen participants, (26.3%), had minimal side effects, which the trial drug could be administered until the end of study. At the 12th week follow-up, 42/49 participants (85.7%) had normal serum Beta-crosslab and 45/49 participants (91.8%) had normal serum N-MID osteocalcin. None showed any decrease in serum P1NP. All participants had slight reduction in serum alkaline phosphatase.
Conclusion: The trial drug could inhibit high bone turnover in about 85% of post-menopausal participants within 12 weeks
of drug administration and no severe side effect took place.

Keywords: Bisphosphonates, Bone resorption, Osteoporosis